title: Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
abstract: BACKGROUND
  Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy.
  
  
  METHODS
  Twenty-four patients who were enrolled in a large randomized trial of thalidomide vs no thalidomide maintenance therapy for myeloma, in which all patients also received zoledronic acid, were recruited to a pharmacokinetic and renal safety sub-study, and followed for up to 16 months.
  
  
  RESULTS
  No significant differences by Wilcoxon rank-sum statistic were found in zoledronic acid pharmacokinetics or renal safety for up to 16 months in patients randomized to thalidomide or not.
  
  
  CONCLUSIONS
  In myeloma patients receiving maintenance therapy, the combination of zoledronic acid and thalidomide appears to confer no additional renal safety risks over zoledronic acid alone.
authors: Department of Haematology and Bone Marrow Transplantation, The Alfred Hospital, Prahan, Victoria, Australia. aspencer@netspace.net.au
authors: Andrew
authors: A
authors: Spencer
authors: Andrew
authors: A
authors: Roberts
authors: Nola
authors: N
authors: Kennedy
authors: Christina
authors: C
authors: Ravera
authors: Serge
authors: S
authors: Cremers
authors: Sanela
authors: S
authors: Bilic
authors: Terry
authors: T
authors: Neeman
authors: Michael
authors: M
authors: Copeman
authors: Horst
authors: H
authors: Schran
authors: Kevin
authors: K
authors: Lynch
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D013792:Thalidomide; D000077211:Zoledronic Acid; D011239:Prednisolone; D003404:Creatinine